Compare Smith & Nephew plc (SNN) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Veritone Inc — how do they compare? Smith & Nephew plc trades at $30.45 (market cap $12.64B), while Veritone Inc trades at $1.13 (market cap $97.60M). The key difference: Smith & Nephew plc is far larger — about 129.5× Veritone Inc's market cap, and Smith & Nephew plc pays a 2.57% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| SNN | VERI | |
|---|---|---|
Market Cap | $12.64B | $97.60M |
Sector | Health | Technology |
52-Week High | $38.70 | $8.39 |
52-Week Low | $28.73 | $1.02 |
Enterprise Value | $15.41B | $129.63M |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
VERI trades at $1.05, up 2.94% today, but remains in a bearish technical trend with negative earnings and cash flow. The company reported a net loss of $111.73M in 2025, with revenue of $92.19M, and faces multiple securities class action lawsuits. Analyst ratings are split evenly between Buy and Hold, with a minority Sell rating, reflecting uncertainty amid financial challenges and legal overhangs.
The outlook is highly speculative due to persistent losses, negative margins, and legal risks. While the low P/S ratio of 0.87 may attract value hunters, the stock carries significant downside risk from operational cash burn and potential settlement costs. Investors should weigh the speculative potential against substantial financial and litigation headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
